HIT Antibodies Undetectable by ELISA Activate Platelets in Mice and Humans

Diagnostic limitations in heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia is a prothrombotic immune-mediated reaction caused by antibodies targeting platelet factor 4 and heparin complexes [1, 2]. Because the resulting platelet activation can lead to life-threatening arterial and venous thrombosis, rapid diagnosis is essential for transitioning patients to non-heparin anticoagulants [3, 2]. Current diagnostic algorithms rely heavily on the enzyme-linked immunosorbent assay (a laboratory technique used to detect and measure antibodies in the blood) to identify these complexes, often using negative results to exclude the condition [4, 5]. However, the clinical utility of these immunoassays depends on the assumption that all pathogenic antibodies bind to the specific complexes presented in the assay [5]. Recent evidence suggests that the diagnostic landscape is more complex than previously understood, particularly regarding antibodies that activate platelets through mechanisms that bypass standard detection.

Identification of ELISA-negative platelet-activating antibodies

Researchers have identified a distinct subset of pathogenic antibodies that are undetectable by the standard platelet factor 4 and heparin enzyme-linked immunosorbent assay (ELISA-negative) but successfully activate platelets in the platelet factor 4-dependent P-selectin expression assay (PEA-positive). The P-selectin expression assay is a functional test that measures the translocation of P-selectin to the platelet surface, which serves as a reliable marker of alpha-granule secretion and cellular activation. These ELISA-negative, PEA-positive antibodies represent a previously unrecognized immune profile in heparin-induced thrombocytopenia, as they lack reactivity in the primary screening tool used by most clinical laboratories yet retain the ability to trigger the prothrombotic cascade. This finding suggests that the standard immunoassay may have a significant blind spot in detecting the full spectrum of antibodies capable of driving the disease.

In a cohort of 11 patients with clinically confirmed heparin-induced thrombocytopenia who tested positive in both the standard ELISA and functional activation assays, the researchers found that ELISA-negative, PEA-positive antibodies accounted for 65 ± 19% of the total platelet-activating immunoglobulin G activity. This data indicates that the majority of the antibody-mediated platelet activation in these patients was driven by a subset of antibodies that would be invisible if tested in isolation by the standard immunoassay. Furthermore, these ELISA-negative, PEA-positive antibodies coexisted with standard ELISA-positive, PEA-positive antibodies in all 11 patients, suggesting that the immune response in heparin-induced thrombocytopenia is more heterogeneous than the current diagnostic model assumes. For the practicing clinician, this coexistence implies that a positive ELISA result may only be capturing a fraction of the total pathogenic antibody burden present in the patient's circulation, potentially underestimating the severity of the prothrombotic state.

Cellular prevalence and structural heterogeneity

To investigate the cellular origins of these pathogenic antibodies, the researchers performed single-cell cloning from seven patients with heparin-induced thrombocytopenia. This process involves isolating individual B-cells (the white blood cells responsible for producing antibodies) and growing them to identify their specific outputs. The study identified 23 PEA-positive antibody-producing B-cell clones, all of which produced antibodies capable of activating platelets in the P-selectin expression assay. This confirms their functional relevance in the disease process and suggests that the immune system's production of heparin-induced thrombocytopenia antibodies is more diverse at the cellular level than previously recognized.

The analysis of these 23 clones revealed a striking disparity between functional activity and immunoassay detection. Among the 23 PEA-positive clones identified, 17 were ELISA-negative, outnumbering the ELISA-positive clones. This finding provides a cellular explanation for why standard immunoassays may underestimate the total pathogenic antibody burden, as the majority of the B-cell clones in this sample produced antibodies that do not react with the standard platelet factor 4 and heparin complex used in ELISA testing. For clinicians, this indicates that the B-cell response in heparin-induced thrombocytopenia is dominated by clones that produce antibodies invisible to the most common screening tool, which may explain cases where clinical symptoms persist despite low or borderline immunoassay titers.

Structural analysis of these antibodies further defined the complexity of the immune response. The researchers found that ELISA-negative, PEA-positive antibodies were heterogeneous, meaning they possessed diverse molecular structures rather than originating from a single, uniform cell line. Despite this diversity, a subset of ELISA-negative, PEA-positive antibodies shared heavy-chain features with ELISA-positive, PEA-positive antibodies. The heavy chain is the larger polypeptide subunit of an antibody that determines its class and much of its binding specificity. This structural overlap suggests a common lineage or shared developmental pathway between the antibodies that are easily detected by ELISA and those that remain hidden, even though their binding behaviors in the laboratory differ significantly.

Mechanisms of platelet activation and binding specificity

The functional profile of ELISA-negative, PEA-positive antibodies closely mirrors that of their ELISA-positive counterparts, suggesting a shared mechanism of pathogenicity despite their different detection profiles. The researchers determined that platelet binding and activation by ELISA-negative, PEA-positive antibodies required the presence of exogenous platelet factor 4, a protein typically released from alpha-granules during platelet activation. This activation process was effectively inhibited by FcgRIIA blockade, which involves blocking the specific receptor on the platelet surface that binds the Fc portion (the tail end) of the antibody. Furthermore, the study found that activation by ELISA-negative, PEA-positive antibodies was inhibited by high-dose heparin, a characteristic feature of heparin-induced thrombocytopenia where excess heparin disrupts the formation of the antigenic complex. The researchers also demonstrated that activation was inhibited by Fab fragments (the antigen-binding portion of an antibody) derived from ELISA-positive, PEA-positive antibodies, indicating that both antibody types likely compete for similar or overlapping binding sites on the target complex.

The binding specificity of these antibodies highlights a unique diagnostic challenge, as they exhibit highly selective reactivity that is not captured by standard laboratory preparations. Although these antibodies lack reactivity to platelet factor 4 and heparin complexes in standard ELISAs, the researchers found that ELISA-negative, PEA-positive antibodies recognize platelet factor 4 on the surface of platelets. This binding is highly specific to the environment of the platelet membrane; notably, these antibodies showed no appreciable binding to platelet factor 4 alone, nor did they react with other related chemokines. Specifically, the antibodies showed no appreciable binding to neutrophil-activating peptide 2 (NAP-2) or interleukin-8 (IL-8), two proteins that share structural similarities with platelet factor 4. These findings suggest that the pathogenic antibodies missed by standard screening tools require the specific conformational presentation of platelet factor 4 as it occurs on the platelet surface, rather than the synthetic complexes used in commercial immunoassays.

Pathogenic relevance and clinical implications

The clinical significance of these findings is underscored by the ability of these antibodies to drive disease pathology in vivo. To confirm that the antibodies missed by standard screening are capable of causing the clinical features of the disorder, the researchers utilized a humanized mouse model of heparin-induced thrombocytopenia. In this model, the ELISA-negative, PEA-positive antibodies induced thrombocytopenia, demonstrating that they are not merely laboratory artifacts but are potent mediators of platelet clearance and consumption. This finding establishes that these antibodies possess the same pathogenic potential as those detected by standard assays, directly contributing to the low platelet counts and associated thrombotic risks seen in patients.

Heparin-induced thrombocytopenia is classically characterized by the development of immunoglobulin G (IgG) antibodies against platelet factor 4 and heparin (PF4/H) complexes. Currently, the PF4/H enzyme-linked immunosorbent assay (ELISA) serves as the standard detection method, and because of its high reported sensitivity, negative ELISA results are commonly used by clinicians to exclude a diagnosis of heparin-induced thrombocytopenia. However, the identification of a prevalent subset of antibodies that are undetectable by PF4/H ELISA but activate platelets in the PF4-dependent P-selectin expression assay (PEA-positive) challenges this diagnostic algorithm. These ELISA-negative, PEA-positive antibodies represent a common, previously unrecognized feature of heparin-induced thrombocytopenia that carries significant functional relevance to disease pathogenesis.

For the practicing clinician, these data suggest that a negative ELISA may not be sufficient to rule out the condition in patients with a high clinical suspicion, such as those with a high 4Ts score (a clinical probability scoring system used to assess the likelihood of heparin-induced thrombocytopenia). Because these antibodies may play an important, or perhaps even central, role in the development of the disease, relying solely on standard immunoassays could lead to underdiagnosis and the inappropriate continuation of heparin therapy. The researchers conclude that defining the exact prevalence, kinetics, and clinical impact of this antibody subset is a high priority, as these antibodies appear to be a fundamental component of the immune response in heparin-induced thrombocytopenia.

References

1. Devarapalli A, Rachamanti R, Singampalli M, Hullur K. Pooled Incidence of Heparin-Induced Thrombocytopenia and Anti-Platelet Factor 4 Antibody Formation Among Adults: A Systematic Review and Meta-Analysis.. Cureus. 2025. doi:10.7759/cureus.98710

2. Hess CN, Becker RC, Alexander JH, Lopes RD. Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.. Journal of thrombosis and thrombolysis. 2012. doi:10.1007/s11239-012-0785-8

3. Napolitano A, Spiezia L, Biolo M, et al. Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review.. Seminars in thrombosis and hemostasis. 2025. doi:10.1055/a-2528-5425

4. Meier RT, Jolink A, Kempe M, et al. PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia.. Transfusion. 2025. doi:10.1111/trf.18242

5. Nilius H, Naas S, Studt J, et al. The dynamic range of immunoassays for heparin-induced thrombocytopenia.. Journal of thrombosis and haemostasis : JTH. 2025. doi:10.1016/j.jtha.2024.10.026